NSE: AUROPHARMA · 19 October 2026
- Aurobindo Pharma Ltd shares fell 3.08% on Monday, closing at ₹1,615.60 after trading between an intraday high of ₹1,679.00 and a low of ₹1,615.60.
- Aurobindo Pharma announced that it received final approval from the US Food & Drug Administration to manufacture and market Perampanel Tablets across strengths ranging from 2 mg to 12 mg. The product is bioequivalent to Catalyst Pharmaceuticals' Fycompa tablets and will be manufactured at APL Healthcare's Unit-IV for a planned Q3FY27 launch. The approved product addresses an estimated U.S. market size of USD 67 million for the twelve months ending August 2026.
- Trading volume was 0.82 times the 20-day average daily volume.
Why is Aurobindo Pharma share price falling on 19 October 2026?
Aurobindo Pharma Ltd shares fell 3.08% on Monday, closing at ₹1,615.60 after trading between an intraday high of ₹1,679.00 and a low of ₹1,615.60.
The stock's decline unfolded against a broader market pullback, as the benchmark Nifty fell 1.11% and the sectoral Nifty Pharma index lost 0.65%. Aurobindo Pharma's down move extended its near-term correction, bringing its 5-day return to -5.35% and its 20-day return to -6.83%.
While no single new corporate filing triggered today's drop, the company recently completed the acquisition of U.S.-based A1 Biochem Labs LLC for a cash consideration of USD 15.247 million through its step-down subsidiary on October 2, 2026, aimed at establishing a dedicated Contract Research, Development and Manufacturing (CRDMO) platform. Additionally, the company received final USFDA approval for Perampanel Tablets on October 3, 2026, which targets an estimated U.S. market size of USD 67 million based on IQVIA MAT data for the twelve months ending August 2026.
7.18 lakh shares traded by 19 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 8.78 lakh shares (0.82 times). The five-day average daily volume was 9.21 lakh shares. Separately, the NSE report for 16 October 2026 showed 4.22 lakh shares delivered, representing 52.91% of that day’s traded volume. The same report recorded 62,540 trades.
Aurobindo Pharma's 3.08% decline reflects broader downward pressure across equity markets and the pharmaceutical sector, aligning with recent negative short-term momentum rather than a specific negative same-day catalyst.
Latest Company Developments
Aurobindo Pharma announced that it received final approval from the US Food & Drug Administration to manufacture and market Perampanel Tablets across strengths ranging from 2 mg to 12 mg. The product is bioequivalent to Catalyst Pharmaceuticals' Fycompa tablets and will be manufactured at APL Healthcare's Unit-IV for a planned Q3FY27 launch. The approved product addresses an estimated U.S. market size of USD 67 million for the twelve months ending August 2026.
Expands the company's central nervous system product portfolio in the U.S. market with a commercial launch planned for the current quarter.
Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma, completed the acquisition of 100% membership interest in U.S.-based A1 Biochem Labs LLC through its step-down subsidiary for a cash consideration of USD 15.247 million. A1 Labs LLC operates a leased scientific facility in Wilmington, North Carolina, providing contract research and chemistry services with historical turnover of USD 5.92 million for the calendar year 2025.
Advances the company's strategic objective of building an integrated CRDMO platform by adding front-end research capabilities to its large-scale API manufacturing operations.
Acrotech Biopharma Inc., a step-down subsidiary of Aurobindo Pharma, announced the U.S. launch of ADQUEY (difamilast 1%) ointment for the treatment of mild-to-moderate atopic dermatitis in patients aged 2 years and older. To support this rollout and future dermatological products, Acrotech established a dedicated dermatology business unit. The product competes in a U.S. market estimated at approximately USD 1.3 billion for the twelve months ending July 2026.
Marks Acrotech's entry into the U.S. dermatology market and establishes a dedicated commercial platform for specialty therapeutic offerings.
Aurobindo Pharma Limited has submitted the Exchange a copy Srutinizers report of AGM held on August 27, 2026. and voting results.
a press release dated October 03, 2026, titled "Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.31% on 30 September 2026. This compares with 16.71% on 30 June 2026, a change of -0.40 percentage points.
The filing reported 44 MF/UTI holders.
Research & Brokerage Views
Maintained a positive outlook citing strong business momentum and growth visibility across key international generic and specialty segments.
What to Watch Next
- Execution and financial contribution of the newly launched ADQUEY ointment in the U.S. dermatology market
- Integration progress and synergy realization from the newly acquired A1 Biochem Labs LLC CRDMO platform
- Commercialization timeline and market uptake for Perampanel Tablets following the recent USFDA approval
- Delivery percentage and cash volume trends relative to the 20-day average volume of 82%
Other Dated Coverage
- Why Aurobindo Pharma Shares Slipped 0.11% Today Amid Sector Weakness | 5 October 2026 — 5 October 2026
- Aurobindo Pharma in Focus After U.S. ADQUEY Launch; What to Watch Today | 1 October 2026 — 1 October 2026
More Aurobindo Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Aurobindo Pharma company news?
Aurobindo Pharma announced that it received final approval from the US Food & Drug Administration to manufacture and market Perampanel Tablets across strengths ranging from 2 mg to 12 mg. The product is bioequivalent to Catalyst Pharmaceuticals' Fycompa tablets and will be manufactured at APL Healthcare's Unit-IV for a planned Q3FY27 launch. The approved product addresses an estimated U.S. market size of USD 67 million for the twelve months ending August 2026.
How strong was Aurobindo Pharma’s trading volume?
7.18 lakh shares traded, 0.82 times the 20-day average daily volume. The price and volume data are dated 19 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.